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Background: ,QÀDPPDWRU\ERZHOGLVHDVH,%'GLDJQRVLVZDVVWLOOEDVHGRQLQYDVLYHH[DPLQDWLRQVXFKDV
HQGRVFRS\DQGKLVWRSDWKRORJ\)HFDOFDOSURWHFWLQZDVDQRQLQYDVLYHLQWHVWLQDOLQÀDPPDWLRQPDUNHUEXWVHYHUDO
VWXG\JLYHDGLIIHUHQWUHVXOWLQLWVGLDJQRVWLFYDOXHDQGFRUUHODWLRQWRLQÀDPPDWRU\ERZHOGLVHDVH7KLVUHVHDUFK
ZDVDLPHGWRSURYHWKDWIHFDOFDOSURWHFWLQH[DPLQDWLRQKDVDKLJKGLDJQRVWLFYDOXHLQGLDJQRVLQJLQÀDPPDWRU\
bowel disease, and also correlate to its clinical stages. 
Method: This is a cross sectional study to do a diagnostic test in several hospital in Jakarta, from September 
 WR)HEUXDU\5HFHLYHURSHUDWLQJFKDUDFWHULVWLF 52&FXUYHZDVPDGH WRJHW IHFDOFDOSURWHFWLQ
diagnostic level and Krusskal Wallis test was performed to identify fecal calprotectin difference among each 
LQÀDPPDWRU\ERZHOGLVHDVHFOLQLFDOVWDJHV
Results: $ WRWDORISDWLHQWVZLWK LQÀDPPDWRU\ERZHOGLVHDVHZDV LQYRYHG LQ WKLV UHVHDUFKEDVHGRQ
FRORQRVFRSLFH[DPLQDWLRQUHVXOW$PRQJWKHPSDWLHQWVZDVFRQ¿UPHGWRKDYHLQWHVWLQDOLQÀDPPDWLRQEDVHG
RQKLVWRSDWKRORJ\UHVXOW)HFDOFDOSURWHFWLQOHYHOZDVIRXQGWREHKLJKHULQSDWLHQWVZLWKLQÀDPPDWRU\ERZHO
GLVHDVHWKDQSDWLHQWVZLWKRXWLQWHVWLQDOLQÀDPPDWLRQJJYVJJS$FXWRIISRLQWRI
JJZDVJDWKHUHGZLWKVHQVLWLYLW\&,VSHFL¿FLW\&,DQG
DUHDXQGHUFXUYH$8&&,$VLJQL¿FDQWGLIIHUHQFHZDVIRXQGEHWZHHQIHFDO
FDOSURWHFWLQLQHDFKLQÀDPPDWRU\ERZHOGLVHDVHFOLQLFDOVWDJHVS
Conclusion:)HFDO FDOSURWHFWLQ KDV D KLJKGLDJQRVWLF YDOXH IRU LQÀDPPDWRU\ERZHO GLVHDVH ,%'DQG
strongly correlate to its disease clinical stages. 
Keywords: IHFDOFDOSURWHFWLQKLVWRSDWKRORJ\LQÀDPPDWRU\ERZHOGLVHDVHFXWRIISRLQWV
$%675$.
Latar belakang: Diagnosis penyakit radang usus masih didasarkan pada pemeriksaan invasif seperti 
HQGRVNRSLGDQKLVWRSDWRORJL)HFDOFDOSURWHFWLQPHUXSDNDQSHWDQGDLQÀDPDVLLQWHVWLQDOQRQLQYDVLI\DQJGDSDW
GLJXQDNDQXQWXNPHPEHGDNDQSHQ\DNLWUDGDQJXVXVGHQJDQSHQ\DNLWLQWHVWLQDOQRQLQÀDPDVLQDPXQVWXGLVWXGL
Volume 16, Number 3, December 2015 167
Fecal Calprotectin Level as Diagnostic Marker for Intestinal Inflammation in Inflammatory Bowel Disease Patients
yang ada masih memberikan perbedaan nilai diagnostik dan hubungannya dengan derajat penyakit radang usus. 
Penelitian ini bertujuan untuk membuktikan bahwa pemeriksaan fecal calprotectin memiliki nilai diagnostik yang 
tinggi untuk mendiagnosis penyakit radang usus serta berhubungan dengan derajat klinis penyakit radang usus.
Metode: Penelitian ini adalah studi potong lintang untuk melakukan uji diagnostik yang dilakukan di 
EHEHUDSDUXPDKVDNLWGL-DNDUWDPXODLEXODQ6HSWHPEHUKLQJJD)HEUXDUL.XUYDUHFHLYHURSHUDWLQJ
characteristic (ROC) dibuat untuk mendapatkan nilai diagnostik fecal calprotectin dan uji Krusskal Wallis untuk 
menilai perbedaan kadar fecal calprotectin menurut derajat penyakit radang usus.
Hasil: Terdapat 71 pasien penyakit radang usus berdasarkan pemeriksaan kolonoskopi diikutkan dalam 
penelitian. Dari pasien tersebut didapatkan sebanyak 57 pasien ditetapkan secara pasti menderita penyakit 
radang usus berdasarkan pemeriksaan histopatologi. Kadar fecal calprotectin lebih tinggi bermakna pada 
SDVLHQSHQ\DNLWUDGDQJXVXVGLEDQGLQJ\DQJEXNDQSHQ\DNLWUDGDQJXVXVJJYVJJS
'LGDSDWNDQQLODLWLWLNSRWRQJJJGHQJDQVHQVLWLYLWDV&,VSHVL¿VLWDV
&,GDQDUHDXQGHUFXUYH$8&&,'LGDSDWNDQSHUEHGDDQEHUPDNQDNDGDU
IHFDOFDOSURWHFWLQSDGDPDVLQJPDVLQJGHUDMDWSHQ\DNLWUDGDQJXVXVS
Simpulan: Pemeriksaan fecal calprotectin memiliki nilai diagnostik yang tinggi untuk mendiagnosis penyakit 
radang usus serta berhubungan dengan derajat penyakit radang usus.
Kata kunci: fecal calprotectin, histopatologi, penyakit radang usus, titik potong
,1752'8&7,21
,QWHVWLQDO LQÀDPPDWLRQZDV WKHPDLQXQGHUO\LQJ
cause of inflammatory bowel disease (IBD) that 
manifest as sign and symptom found in patients. 
Nowadays, endoscopic examination was still the gold 
VWDQGDUGRILQWHVWLQDOLQÀDPPDWLRQGLDJQRVLV1,2 Other 
non-invasive and less expensive examination that 
ZDVVWLOOXVHGWRSUHGLFWLQWHVWLQDOLQÀDPPDWLRQZDV
erythrocyte sedimentation rate and C reactive protein.3,4 
%XWWKLVH[DPLQDWLRQVZHUHQRWVHQVLWLYHQRUVSHFL¿F
WRVKRZDQLQWHVWLQDOLQÀDPPDWLRQ4 
Previous study reported a development of decal 
LQÀDPPDWLRQPDUNHUWRGLDJQRVH,%'&DOSURWHFWLQ
IRXQG E\)DJHUKRO LQ ZDV WKH¿UVW LQWHVWLQDO
inflammation in fecal. Calprotectin was a 36 kD 
protein that bind to calcium and zinc. Most of 
calprotectin derived from neutrophil and monocyte 
with antimicrobe and antiproliferation activity. In 
LQWHVWLQDOLQÀDPPDWLRQFDOSURWHFWLQFRQFHQWUDWLRQLQ
IHFDOZDVWLPHVKLJHUWKDQSODVPDDQGVLJQL¿FDQWO\
higher in IBD patients.5,6 Is that fecal calprotectin (FC) 
KDVDKLJKYDOXHLQGLDJQRVLQJ,%'"3UHYLRXVVWXG\
have shown a different diagnostic value with different 
cut off point for fecal calptrotectin.7,8,9 One of the study 
FRQGXFWHGLQ,QGRQHVLDUHSRUWHGDVLJQL¿FDQWGLIIHUHQFH
between fecal calprotectin in IBD and gastrointestinal 
functional disorder, but did not investigate its cut off 
points and its correlation with IBD severity.10 
Fecal calprotectin concentration was found to 
have a correlation to IBD clinical severity, especially 
in ulcerative colitis patients.11,12,13 Otherwise, several 
studies were not found any correlation between fecal 
calprotectin and IBD clinical severity.14,15,16 This study 
was aimed to investigate fecal calprotectin level that 
helps to diagnose IBD, and its application to set IBD 
severity, and also act as treatment evaluation and 
prognostic tools.
0(7+2'
7KLVLVDFURVVVHFWLRQDOVWXG\WR¿QGDQHZFXWRII
points in diagnostic test. This study was conducted 
in Cipto Mangunkusumo Hospital, Jakarta and other 
hospitals, such as Islam Hospital Jakarta, MMC 
Hospital Jakarta, and Pelni Hospital Jakarta from 
September 2014 to February 2015. Target population 
was suspected IBD patients with symptoms of chronic 
diarrhea, hematoschezia, and abdominal pain that come 
to gastroenterology division and Cipto Mangunkusumo 
Hospital and other hospitals wards. Population was 
SDWLHQWV IXO¿O WKH LQFOXVLRQ FULWHULD DQGZLOOLQJ WR
participate on this study. Subject was patients with 
,%'¿QGLQJVGXULQJFRORQRVFRS\H[DPLQDWLRQ1RQ
probability sampling with consecutive sampling was 
used. Inclusion criteria was patients with clinical 
symptoms of IBD (chronic diarrhea, hematoschezia, 
and abdominal pain), willing to participate on this study 
by signing informed concent form, willing to undergo 
FRORQRVFRS\H[DPLQDWLRQDQG,%'¿QGLQJVZDVIRXQG
during colonoscopy. Exclusion criteria was patients 
using NSAID, PPI, or in IBD medication.
3DWLHQWVZLWK ,%'¿QGLQJV GXULQJ FRORQRVFRS\
was underwent a biopsy in Pathology Department of 
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Cipto Mangunkusumo Hospital and other hospital to 
JHWWKHGH¿QLWHGLDJQRVLVDQGWKHIHFDOZDVWDNHQ$OO
fecal taken from the patients was examined in Prodia 
Laboratory Clinic in Jakarta to get fecal calprotectin 
concentration level. During laboratory examination, 
fecal was homogenized and saved in liquid form 
in -20oC. Fecal calprotectin examination was using 
enzyme link immune sorbent assay (ELISA), PhiCalR 
calprotectin ELISA Kit, by quantitative sandwich 
enzyme immunoassay technique with dual monoclonal 
antibody specific to bind to human calprotectin. 
Conoloscopy examination was performed by internist 
under supervision of gastroenterology-hepatologist 
consultant where diagnosis was made by the consultant 
during the colonoscopy examination. 
Data was analysed using SPSS software version 
21. Fecal calprotectin cut off point was known from 
ROC curve. Data presented in 2 x 2 table to get 
positive predictive value (PPV), negative predictive 
value (NPV), positive possibility ratio (PPR), and 
negative possibility ratio (NPR). Differences between 
mean fecal calprotectin level and IBD severity was 
analysed using Kruskal Wallis test, continued by post 
hoc analysis using Mann Whitney test, considered 
positive if p < 0.05. 
5(68/76
During 6 months period, from September 2014 to 
February 2015, 71 patients with IBD suggestion was 
involved in this research. From all subjects, based 
on pathological examination, 57 (80%) subjects was 
GLDJQRVHG,%'GH¿QLWLYHZKLOHWKHUHVWSDWLHQWV
have non-IBD diagnosis (infective colitis, reactive 
FROLWLVQRQVSHFL¿FFROLWLV)RUW\¿YHRI,%'SDWLHQWV
was having ulcerative colitis and 12 patients having 
Chron’s Disease. Among all IBD diagnosed patients, 
disease severity was vary between mild (10 patients), 
moderate (18 patients), and severe (29 patients) based 
RQ7UXHORYHDQG:LWWVFODVVL¿FDWLRQRIXOFHUDWLYHFROLWLV
DQG7KH+DUYH\%UDGVKDZFODVVL¿FDWLRQIRU&KURQ¶V
Disease. 
In ROC curve, fecal calprotectin with 179,3 μg/g 
as the best cut off value with 96% sensitivity (95% CI: 
VSHFL¿FLW\&,DQG
99,5% area under curve (AUC) (95% CI: 0,98-1,00). 
&XWRIIOLQHLGHQWL¿FDWLRQLQWKHFXUYHZDVVKRZQRQ
Figure 1. 
7DEOH&KDUDFWHULVWLFRISDWLHQWVEDVHGRQ,%'DQGQRQ,%'
GLDJQRVHGJURXS
9DULDEOH ,%'Q 
1RQ,%'
Q  p
Gender, %
 Male 32 (56.1) 8 (57.1)
 Female 25 (43.9) 6 (42.9)
Age, median 41 (17-75) 32.5 (20-60)
Hemoglobin, 
mean
11.02 (SD 1.96) 13.24 (SD 1.44) < 0.001
Leukocyte, 
median
8910  
(2200-39120)
7565  
(4760-13310)
0.751
ESR, median 40 (10-139) 26.21 (10-55) < 0.005
FC, median 553.8 (144-785) 76.95 (56-190) < 0.001
,QIHFWLYH FROLWLV UHDFWLYH FROLWLV QRQVSHFL¿F FROLWLV ,%' LQÀDPPDWRU\
bowel disease; SD: standar deviation; ESR: erythrocyte sedimentation rate; 
 FC: fecal calprotectin
Fecal calprotectin level
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)LJXUH&XUYHWRLGHQWLI\FXWRIIOLQHEHWZHHQVHQVLWLYLW\DQG
VSHFL¿FLW\RIIHFDOFDOSURWHFWLQOHYHOLQGLDJQRVLQJ,%'
Based on cut off points 179.3 μg/g of fecal 
calprotectin level and histopathology result, a cross 
tabulation (2 x 2 table) was made between IBD and 
fecal calprotectin value to get IBD predictive value. 
According to cross tabulation, positive predictive 
value (PPV) was 98% (95% CI: 0.91-1.0), negative 
predictive value (NPV) was 87% (95% CI: 0.62-0.96), 
positive possibility ratio (PPR) was 13.51 (95% CI: 
2.18-83.82), and negative possibility ratio (NPR) was 
0.04 (95% CI: 0.01-0.15) (Tabel 2).
7DEOH  &URVV WDEXODWLRQ EHWZHHQ FXW RII YDOXH RI IHFDO
FDOSURWHFWLQDQG,%'
9DULDEOH ,%' 7RWDO<HV 1R
Fecal calprotectin

< 179.3
55
2
1
13
56
15
Total 57 14 71
,%'LQÀDPPDWRU\ERZHOGLVHDVH
Multivariate analysis using Kruskal Wallis test 
VKRZHGDVLJQL¿FDQWGLIIHUHQFHEHWZHHQPHGLDQIHFDO
calprotectin and erythrocyte sedimentation rate (ESR) in 
each clinical stage of IBD (Table 3). This showed that the 
more severe IBD, the higher fecal calprotectin and ESR 
level found in patients. Post hoc analysis using Mann 
:KLWQH\WHVWVKRZHGDVLJQL¿FDQWGLIIHUHQFHVLQDOO,%'
stages: between mild and moderate IBD, mild and severe 
IBD, and moderate and severe IBD (Figure 2).
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W ф Ϭ͕Ϭϱ
ŵŝůĚ ŵŽĚĞƌĂƚĞ ƐĞǀĞƌĞ
/
& ͗ ĨĞĐĂů
ĐĂůƉƌŽƚĞĐƚŝŶ
/ ͗ ŝŶĨůĂŵŵĂƚŽƌǇ
ďŽǁĞů ĚŝƐĞĂƐĞ
)LJXUH'LIIHUHQFHEHWZHHQIHFDOFDOSURWHFWLQ)&OHYHOLQHDFK
,%'FOLQLFDOVWDJHVXVLQJ0DQQ:KLWQH\DQDO\VLV
Fecal calprotectin level of 179,3 μg/g was choosen 
as the best cut-off point with 96% sensitivity (95% CI: 
DQGVSHFL¿FLW\&,
with 99.5% area under curve (AUC) (95% CI: 0.98-
1.00) in diagnosing IBD. This result means that the 
ability of fecal calprotectin to eliminate IBD diagnosis 
when its level was under 179.3 μg/g was as much as 
VHEHVDU  DQG WR GLDJQRVH ,%'GH¿QLWHO\ZKHQ
its level was above 179.3 μg/g was as much as 96%. 
This cut off point give a high diagnostic value of fecal 
calprotectin to diagnose IBD. 
Although it is slightly higher (179.3 μg/g), this 
result was not different with other cut-off point in 
different study (100μg/g, 150μg/g).8,9 A higher cut 
off point in this study was estimated because there 
was no fecal culture in all subject, except polymerase 
chain reaction (PCR) tuberculose (PCR-Tb) in Chron’s 
disease suggested patients. 
Immunologic mediators were played an important 
role in IBD etiopathogenesis. Intestinal infection and 
spicy hot dietary (cabage) was assumed to increase 
LQWHVWLQDOLQÀDPPDWLRQ7KLVFRQGLWLRQZDVEHOLHYHG
to manipulate immune system to trigger chronic 
LQÀDPPDWLRQSURFHVVUHVXOWLQJLQ,%'3,22 In Indonesia, 
with high intestinal infection prevalence, it is hard 
to differentiate between IBD and infection intestinal 
LQÀDPPDWLRQ7KLVZDVFDXVHGE\WKHKLJKIUHTXHQF\
of IBD and infection coincidence, even that infection 
was one of the cause of IBD. Infection process do 
not eliminate IBD diagnosis. Therefore, in this study, 
,%'ZDVGLDJQRVHGEDVHGRQFRORQRVFRSLF¿QGLQJV
and histopathology without infection examination. 
Based on those cut off points, a cross tabulation was 
made between IBD and fecal calprotectin level, so 
that positive predictive value (PPV) of 98% (95% CI: 
0.91-1.0), negative predictive value (NPV) of 87% 
(95% CI: 0.62-0.96), positive possibility ratio (PPR) 
of 13,51 (95% CI: 2.18-83.82), and negative possibility 
ratio (NPR) of 0.04 ( 95% CI: 0.01-0.15). 
In daily clinical practice, both four value above 
was important. Based on PPV and NPV, if patients 
had fecal calprotectin level higher than 179.3 μg/g the 
patients has a possibility to have IBD for 98%, dan if 
7DEOH&RPSDULVRQEHWZHHQIHFDOFDOSURWHFWLQOHYHOKDHPRJORELQOHXNRF\WHDQGHU\WKURF\WH
VHGLPHQWDWLRQUDWHLQHDFK,%'VWDJHV
9DULDEOH ,%' p0LOG 0RGHUDWH 6HYHUH
FC 243.10 (144-281) 399.45 (326-539) 689.7 (554-785) < 0.001*
Hb 11.75 (SD 2.23) 10.93 (SD 1.91) 10.83 (SD 1.91) 0.440
Leukocyte 9655 (5040-39120) 7645 (2200-4270) 8730 (2300-17140) 0.171*
ESR 26.5 (15-60) 37 (10-139) 44 (10-126) < 0.05*
.UXVNDO:DOOLVWHVW,%'LQÀDPPDWRU\ERZHOGLVHDVH)&IHFDOFDOSURWHFWLQ+E+HPRJORELQ(65HU\WKURF\WH
sedimentation rate
',6&866,21
Nowadays, endoscopy examination still become the 
JROGVWDQGDUGLQLQWHVWLQDOLQÀDPPDWLRQHYDOXDWLRQ1,2 
Colonoscopy diagnostic accuracy in IBD case was 
89% with 4% error rate and 7% unreliable result.1 This 
study showed that endoscopy still the best modalities 
to diagnose IBD. Median fecal calprotectin level was 
found to be higher in IBD patients compared to non-
,%'SDWLHQWVZKLFKKDYHORZHULQWHVWLQDOLQÀDPPDWLRQ
(553,8 μg/g vs. 76,95 μg/g, respectively). All patients 
in this study have a fecal calprotectin level above cut 
RIISRLQWEHFDXVHRIWKHLQWHVWLQDOLQÀDPPDWLRQIRXQG
in all patients. 
,QFUHDVLQJIHFDOFDOSURWHFWLQOHYHOZDVXQVSHFL¿HG
for IBD, because this condition also found in 
other inflammation situation, such as infection, 
colorectal cancer, coeliac disease, microscopic colitis, 
and civerticulosis. The use of non-steroidal anti-
LQÀDPPDWRU\ GUXJV 16$,'V DOVR LQFUHDVH IHFDO
calprotectin level, correlate to higher enteropathy 
incidence.17 Proton pump inhibitor (PPI) was also 
believed to increase fecal calprotectin level.6
Previous study showed that fecal calprotectin was 
an important marker to differentiate IBD and other 
non-inflammatory intestinal disease.18,19,20 Patients 
with non-organic disease, such as IBS, showed a lower 
fecal calprotectin level than organic disease, especially 
IBD. Several studies was using cut-off point of 50 
μg/g fecal calprotectin level as positive test result to 
decide whether this patients have to undergo further 
endoscopic examination to eliminate other organic 
intestinal disorder.7,21
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fecal calprotectin level lower than 179.3 μg/g patients 
have a possibility of non-IBD for 87%. Patients with 
fecal calprotectin higher than 179.3 μg/g have a 13.51 
times risk to have IBD than patients with low fecal 
calprotectin. This result showed that fecal calprotectin 
has a high clinical value in diagnosing IBD, so that it 
could be used as good early laboratory parameter in 
diagnosing IBD from clinical symptoms suggestive of 
,%',QWKLVVWXG\WKHUHZHUHDOVRVLJQL¿FDQWGLIIHUHQFH
among median fecal calprotectin level in each IBD 
clinical stages. This means that the more severe IBD, 
the higher its fecal calprotectin level. Post hoc analysis 
VKRZHGDVLJQL¿FDQWGLIIHUHQFH LQ IHFDOFDOSURWHFWLQ
level among all IBD stages, in mild-moderate, mild-
severe, and moderate-severe. 
IBD clinical history was characterized by active 
and remission phase. Remission phase was caused by 
therapy, but sometimes could be spontaneous. With 
this chronic exacerbation remision characteristic in 
IBD, several clinical criteria was made to identify its 
remission phase and to evaluate its therapy process. 
7UXHORYHDQG:LWWVFODVVL¿FDWLRQZDVXVHGWRLGHQWLI\
ulcerative colitis clinical stages, divided into severe, 
moderate, and mild (remission) based on bloody 
diarrhea frequency, presence of fever, severity of 
anemia, and erythrocyte sedimentation rate (ESR).2,23 
The Harvey-Bradshaw score, on the other hand, was 
used to identify clinical stages of Chron’s disease, 
classified as severe (markedly active), moderate 
(moderately active), and mild (remission) based on 
general condition status, abdominal pain, abdominal 
mass, diarrhea, and complications occured.2,24
This result was support several studies that reported 
a correlation between fecal calprotectin level with IBD 
clinical stages.11,12,13 $VLJQL¿FDQWGLIIHUHQFHLQPHGLDQ
fecal calprotectin level among three IBD clinical 
stages in this study showed that fecal calprotectin was 
clinically correlated to IBD stages, so that it can be 
used to identify IBD clinical stages. Therefore, fecal 
calprotectin was proposed to be a laboratory parameter 
used to evaluate the successful of IBD therapy and 
reduce the need of colonoscopy in primary settings. 
This study have some limitations. Patients distribution 
based on IBD stages was imbalance, so that it less 
representative. It also need a longer period of sampling 
to get higher sample number, so that more balance and 
accurate result will be gathered. 
In this study, histopathology examination from 
biopsy specimen was done in pathology laboratory 
in different hospital, so that it was examined by 
different pathologist. This could lead to variation bias 
and interfere result validation. Infection examination, 
which is undone in this study, was estimated to have a 
contribution in deciding fecal calprotectin cut off point. 
A further study with better research methodology was 
needed to get more valid result, so that the result could 
by applicable for daily clinical practice.
&21&/86,21
Fecal calprotectin examination has a high clinical 
YDOXHLQGLDJQRVLQJLQÀDPPDWRU\ERZHOGLVHDVH,%'
with 179,3 μg/g cut off points, 96% sensitivity, and 
 VSHFL¿FLW\0HGLDQ RI IHFDO FDOSURWHFWLQ OHYHO
ZDVVLJQL¿FDQWO\GLIIHUHQWDPRQJGLIIHUHQW,%'VWDJHV
(mild, moderate, severe). A further prospective study 
using fecal calprotectin was needed to investigate 
its capability in IBD therapy evaluation, and also to 
make fecal calprotectin as prediction model of IBD 
diagnosis without invasive procedure. It also need a 
further study with better research methodology to get 
more valid result. 
7DEOH7UXHORYHDQG:LWWVFODVVL¿FDWLRQ
6HYHUH 0RGHUDWH 5HPLVVLRQ
Bloody diarrhea/day < 4 4 or more, if DQG
Heart rate < 90 x/minute [PLQXWH > 90 x/minute, or
Temperature < 37,5 oC oC > 37,8 oC or
Hemoglobin > 11,5 g/dL JG/ < 10,5 g/dL or
Erythrocyte 
sedimentation rate
< 20 mm/hour PPKRXU > 30 mm/hour 
7DEOH7KH+DUYH\±%UDGVKDZVLPSOL¿HG&URKQ¶VGLVHDVHDFWLYLW\LQGH[
6FRUH     
General status Good Slightly good Poor Very poor Worst
Abdominal pain No Mild Moderate Severe
Abdominal mass No Maybe Yes &RQ¿UPHGZLWKSDLQ
Diarrhea 1 for liquid consistency diarrhea/day
Complication 1 for each disease : arthralgia, uveitis, erythema nodosum, pyoderma 
JDQJUHQRXVDSKWKRXVXOFHUDQDO¿VVXUHQHZ¿VWXODRUDEVFHVV
7RWDOGLVHDVHDFWLYLW\VFRUH PLOGUHPLVVLRQ PRGHUDWH VHYHUH
Volume 16, Number 3, December 2015 171
Fecal Calprotectin Level as Diagnostic Marker for Intestinal Inflammation in Inflammatory Bowel Disease Patients
5()(5(1&(6
1. .HORPSRN6WXGL,QÀDPPDWRU\%RZHO'LVHDVH,%',QGRQHVLD
.RQVHQVXV QDVLRQDO SHQDWDODNVDQDDQ LQÀDPPDWRU\ ERZHO
disease (IBD) di Indonesia. Perkumpulan Gastroenterologi 
Indonesia Jakarta 2011.
2. Bernstein CN, Fried M, Krabshuis JH, Cohen H, Eliakim R, 
Fedail S, et al. World gastroenterology organization practice 
guidelines for the diagnosis and management of IBD in 2010. 
,QÀDPP%RZHO'LV
3. Abdullah M, Syam AF, Simadibrata M, Gunawan J, Makmun 
D, Rani AZ. New insights on the pathomechanisms of 
LQÀDPPDWRU\ERZHOGLVHDVH-'LJ'LV
4. Turkay C, Kasapoglu B. Non-invasive methods in evaluation 
RILQÀDPPDWRU\ERZHOGLVHDVHZKHUHGRZHVWDQGQRZ"$Q
update. Clinics 2010;65:221-31.
5. Gearry R, Barclay M, Florkowski C, George P, Walmsley T. 
Faecal calprotectin: the case for a novel non-invasive way of 
DVVHVVLQJLQWHVWLQDOLQÀDPPDWLRQ1=0HG-
6. Smith LA, Gaya DR. Utility of faecal calprotectin analysis 
LQDGXOWLQÀDPPDWRU\ERZHOGLVHDVH:RUOG-*DVWURHQWHURO
2012;18:6782-9.
7. Gisbert JP, McNicholl AG. Questions and answers on the role 
RIIDHFDOFDOSURWHFWLQDVDELRORJLFDOPDUNHULQLQÀDPPDWRU\
bowel disease. Dig Liver Dis 2009;41:56–66.
8. Von Roon AC, Karamountzos L, Purkayastha S, Reese GE, 
Darzi AW, Teare JP, et al. Diagnostic precision of fecal 
FDOSURWHFWLQ IRU LQÀDPPDWRU\ERZHOGLVHDVHDQGFRORUHFWDO
malignancy. Am J Gastroenterol 2007;102:803-13.
9. Konikoff MR, Denson LA. Role of fecal calprotectin as a 
ELRPDUNHURILQWHVWLQDOLQÀDPPDWLRQLQLQÀDPPDWRU\ERZHO
GLVHDVH,QÀDPP%RZHO'LV
10. Rosalyn S. Gambaran kadar calprotectin feses dengan teknik 
(/,6$SDGDLQÀDPPDWRU\ERZHOGLVHDVH,%'GDQJDQJJXDQ
fungsional saluran cerna [Tesis]. Patologi Klinik: Universitas 
Indonesia 2012.
11. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen 
A, Dobos GJ. Non-invasive markers in the assessment of 
intestinal inflammation in inflammatory bowel diseases: 
performance of fecal lactoferrin, calprotectin, and PMN-
elastase, CRP, and clinical indices. Am J Gastroenterol 
2008;103:162–9.
12. Xiang JY, Quyang Q, Dong Li G, Xiao NP. Clinical value of 
fecal calprotectin in determining disease activity of ulcerative 
colitis. World J Gastroenterol 2008;14:53-7.
13. Eder P, Eder KS, Kazmierczak IK, Linke K. Clinical utility 
of the assessment of fecal calprotectin in Lesniowski-Crohn’s 
disease. Pol Arch Med Wewn 2008;118:622-5.
14. Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen 
U, Farkkila M. Crohn’s disease activity assessed by fecal 
calprotectin and lactoferrin: correlation with Crohn’s disease 
DFWLYLW\LQGH[DQGHQGRVFRSLF¿QGLQJV,QÀDPP%RZHO'LV
2008;14:40-6.
15. Jones J, Loftus EV, Panaccione R, Chen LS, Peterson S, Mc-
Connell J, et al. Relationships between disease activity and 
serum and fecal biomarkers in patients with Crohn’s disease. 
Clin Gastroenterol Hepatol 2008;6:1218-24.
16. Gaya DR, Lyon TDB, Duncan A, Neilly JB, Han S, Howell J, 
et al. Faecal calprotectin in the assessment of Crohn’s disease 
activity. Q J Med 2005;98:435-41.
17. Tibble JA, Sigthorsson G, Foster R, Scott D, Fagerhol MK, 
Roseth A, et al. High prevalence of NSAID enteropathy as 
shown by a simple faecal test. Gut 1999;45:362-6.
18. Erbayrak M, Turkay C, Eraslan E, Cetinkaya H, Kasapoglu 
B, Bektas M. The Rule of fecal calprotectin in investigating 
LQÀDPPDWRU\ERZHOGLVHDVHV&OLQLFV
19. Mehrjardi A, Saber AM, Mirskandari M, Ebrahimi DN, 
Iranikhah T. Comparison of fecal calprotectin level in 
LQÀDPPDWRU\ERZHOGLVHDVHDQG LUULWDEOHERZHOV\QGURPH
Govaresh 2010;14:275-8.
20. Gil SA, Braverman D, Stankiewics H, Shitrit D, Peled N, 
Paz K. Fecal calprotectin as a predictor of abnormal colonic 
histology. Dis Colon Rectum 2007;00:1-6.
21. Burri E, Beglinger C. Faecal calprotectin-a useful tool in 
WKHPDQDJHPHQWRILQÀDPPDWRU\ERZHOGLVHDVH6ZLVV0HG
Wkly 2012;142:1-12.
22. Tilg H. Diet and intestinal immunity. N Engl J Med 
2012;366:181-3.
23. Dignass A, Eliakim R, Magro F, Maaser C, Chower Y,Geboes 
K, et al. Second European evidence-based consensus on the 
GLDJQRVLVDQGPDQDJHPHQWRIXOFHUDWLYHFROLWLVGH¿QLWLRQV
and diagnosis. J Crohns Colitis 2012;647:1-26.
24. Assche GV, Dignass A, Panes J, Beaugerie L, Karagiannis J, 
Allez M, et al. The second European evidence-based consensus 
RQWKHGLDJQRVLVDQGPDQDJHPHQWRI&URKQ¶VGLVHDVHGH¿QLWLRQV
and diagnosis. J Crohns Colitis 2010;4:7-27.
